Alimera Sciences, Inc. (NASDAQ:ALIM) SVP Philip Ashman sold 25,500 shares of the stock in a transaction on Friday, January 19th. The shares were sold at an average price of $1.20, for a total value of $30,600.00. Following the completion of the sale, the senior vice president now owns 12,750 shares in the company, valued at approximately $15,300. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Philip Ashman also recently made the following trade(s):
- On Wednesday, January 17th, Philip Ashman sold 25,500 shares of Alimera Sciences stock. The shares were sold at an average price of $1.23, for a total value of $31,365.00.
Shares of Alimera Sciences, Inc. (NASDAQ ALIM) traded down $0.04 during midday trading on Friday, reaching $1.20. The company’s stock had a trading volume of 328,891 shares, compared to its average volume of 129,121. The company has a current ratio of 4.84, a quick ratio of 4.65 and a debt-to-equity ratio of -0.71. Alimera Sciences, Inc. has a 52-week low of $1.11 and a 52-week high of $1.72.
A hedge fund recently raised its stake in Alimera Sciences stock. Stonepine Capital Management LLC raised its position in Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 477,226 shares of the biopharmaceutical company’s stock after buying an additional 292,399 shares during the quarter. Alimera Sciences accounts for 0.4% of Stonepine Capital Management LLC’s holdings, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned 0.69% of Alimera Sciences worth $644,000 at the end of the most recent reporting period. 41.78% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. ValuEngine cut Alimera Sciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 3rd. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Alimera Sciences in a research note on Wednesday, November 22nd. Finally, Cowen restated a “buy” rating on shares of Alimera Sciences in a research note on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Alimera Sciences has an average rating of “Hold” and a consensus target price of $3.38.
COPYRIGHT VIOLATION WARNING: “Alimera Sciences, Inc. (ALIM) SVP Philip Ashman Sells 25,500 Shares” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3148979/alimera-sciences-inc-alim-svp-philip-ashman-sells-25500-shares.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.